$SWTX

SpringWorks Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

PRICE

$27.82 ▲1.457%

Last Close

VOLUME

1,155,523

DAY RANGE

27.315 - 29

52 WEEK

13.6 - 89.75

Join Discuss about SWTX with like-minded investors

profile
@dros #droscrew
recently

Increasing unusual call volume: $SWBI $ANF $RENT $CLX $VNET Increasing unusual put volume: $ANF $AVYA $BBY $ROST $SPG $SWTX $WOOF $EXPR

112 Replies 12 👍 13 🔥

profile
@Benlax #droscrew
recently

$PSNL Announces Collaboration with MapKure (jointly owned by $BGNE & $SWTX) to Use Personalis’ NeXT Platform for Clinical Trials and Companion Diagnostic Development

147 Replies 8 👍 11 🔥

Key Metrics

Market Cap

1.38 B

Beta

0

Avg. Volume

1.34 M

Shares Outstanding

49.41 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-04

Next Dividend Date

Company Information

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks' strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.

Website:

HQ: ,

Related News